This edition of the Carnival of Biotechnology features commentary on regulatory problems and progress, international development, and failed commercialization strategies.
The Washington Post has a report from the Institute of Medicine claiming that the drug review system is broken, and calling for changes.
The Patent Barista’s update the road to biogenerics, profiling recent bills aimed at formalizing processes to approve generic versions of biologic drugs.
Pharmalicensing has a post on the costs and benefits of clinical trials in India.
Solata Advisors have a brief post on the evils of starting from technology – it is preferable to start a company by seeking to serve a market rather than develop a technology for which no market may exist.